HK1107261A1 - Method of wound healing using a2b adenosine receptor antagonists - Google Patents

Method of wound healing using a2b adenosine receptor antagonists

Info

Publication number
HK1107261A1
HK1107261A1 HK07112965.9A HK07112965A HK1107261A1 HK 1107261 A1 HK1107261 A1 HK 1107261A1 HK 07112965 A HK07112965 A HK 07112965A HK 1107261 A1 HK1107261 A1 HK 1107261A1
Authority
HK
Hong Kong
Prior art keywords
wound healing
receptor antagonists
adenosine receptor
adenosine
antagonists
Prior art date
Application number
HK07112965.9A
Other languages
English (en)
Inventor
Dewan Zeng
Luiz Belardinelli
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1107261A1 publication Critical patent/HK1107261A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HK07112965.9A 2004-09-01 2007-11-27 Method of wound healing using a2b adenosine receptor antagonists HK1107261A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60667504P 2004-09-01 2004-09-01
PCT/US2005/030838 WO2006028810A2 (en) 2004-09-01 2005-08-30 Method of wound healing using a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
HK1107261A1 true HK1107261A1 (en) 2008-04-03

Family

ID=35695744

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112965.9A HK1107261A1 (en) 2004-09-01 2007-11-27 Method of wound healing using a2b adenosine receptor antagonists

Country Status (22)

Country Link
US (1) US20060058322A1 (ko)
EP (1) EP1789053B1 (ko)
JP (2) JP4929173B2 (ko)
KR (1) KR101247528B1 (ko)
CN (1) CN101043889B (ko)
AU (1) AU2005282860B2 (ko)
CA (1) CA2578702A1 (ko)
DK (1) DK1789053T3 (ko)
ES (1) ES2387653T3 (ko)
HK (1) HK1107261A1 (ko)
HR (1) HRP20120712T1 (ko)
IL (1) IL181634A (ko)
MX (1) MX2007002437A (ko)
NO (1) NO20071718L (ko)
NZ (1) NZ553487A (ko)
PL (1) PL1789053T3 (ko)
PT (1) PT1789053E (ko)
RS (1) RS52455B (ko)
RU (1) RU2385322C2 (ko)
SI (1) SI1789053T1 (ko)
WO (1) WO2006028810A2 (ko)
ZA (1) ZA200701777B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2440467T3 (es) * 2003-08-25 2014-01-29 Dogwood Pharmaceuticals, Inc. 8-heteroaril xantinas substituidas
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
CN102015712A (zh) * 2008-03-26 2011-04-13 阿德维纳斯治疗私人有限公司 作为腺苷受体拮抗剂的杂环化合物
JP2021517164A (ja) 2018-03-05 2021-07-15 テオン セラピューティクス，インク． アデノシン受容体アンタゴニストおよびその使用
CN108864114B (zh) * 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
GB9415529D0 (en) * 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
JP2003535818A (ja) * 2000-02-17 2003-12-02 スィーヴィー セラピューティクス インコーポレイテッド 哺乳動物細胞増殖を媒介するａ２ｂアデノシンリセプタ拮抗剤の同定および使用方法
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US7490726B2 (en) * 2001-09-06 2009-02-17 Alexander Virvo Soft toy holder
US6437154B1 (en) * 2001-09-28 2002-08-20 Council Of Scientific And Industrial Research Process for the preparation of 10-deacetylbaccatin III
NZ532816A (en) * 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP4051481B2 (ja) * 2002-11-29 2008-02-27 ヤマハマリン株式会社 船外機
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
CA2544193C (en) * 2003-10-31 2012-03-27 Cv Therapeutics, Inc. A2b adenosine receptor antagonists

Also Published As

Publication number Publication date
KR20070047816A (ko) 2007-05-07
RU2007107605A (ru) 2008-09-10
AU2005282860B2 (en) 2012-03-22
JP2008511654A (ja) 2008-04-17
PL1789053T3 (pl) 2012-12-31
KR101247528B1 (ko) 2013-04-15
CN101043889A (zh) 2007-09-26
SI1789053T1 (sl) 2012-09-28
DK1789053T3 (da) 2012-08-06
EP1789053A2 (en) 2007-05-30
RU2385322C2 (ru) 2010-03-27
IL181634A0 (en) 2007-07-04
WO2006028810A2 (en) 2006-03-16
MX2007002437A (es) 2007-08-14
ES2387653T3 (es) 2012-09-27
NZ553487A (en) 2010-09-30
CA2578702A1 (en) 2006-03-16
JP4929173B2 (ja) 2012-05-09
JP2011246492A (ja) 2011-12-08
CN101043889B (zh) 2010-11-03
RS52455B (en) 2013-02-28
AU2005282860A1 (en) 2006-03-16
NO20071718L (no) 2007-03-30
ZA200701777B (en) 2008-09-25
IL181634A (en) 2015-05-31
EP1789053B1 (en) 2012-06-13
HRP20120712T1 (hr) 2012-10-31
US20060058322A1 (en) 2006-03-16
WO2006028810A3 (en) 2006-09-28
PT1789053E (pt) 2012-08-09

Similar Documents

Publication Publication Date Title
HK1107261A1 (en) Method of wound healing using a2b adenosine receptor antagonists
IL178365A (en) Selective antagonists of a2a adenosine receptors
IL175759A0 (en) A2b adenosine receptor antagonists
IL182493A0 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
ZA200710878B (en) Prodrugs of A2B adenosine receptor antagonists
ZA200703229B (en) Use of A2A adenosine receptor agonists
GB0611154D0 (en) Novel receptor antagonists and their methods of use
HK1100937A1 (en) Hydroisoindoline tachykinin receptor antagonists
EP1726660A4 (en) METHOD OF MEASURING GLYCOPROTEINS
SI1786744T1 (sl) Postopek za zaviranje vezave mavca in pripravkov iz mavca
IL182528A0 (en) Purine derivatives for use as adenosin a-2a receptor antagonists
EP1734966A4 (en) USE OF PIPERAZINYLPIPERIDINE DERIVATIVES AS ANTAGONISTS OF CHEMOKINE RECEPTORS
EP2032797A4 (en) ADENOSINE A2B RECEPTOR ANTAGONISTS
EP1751175A4 (en) ANTAGONISTS OF THE INTERLEUKIN-1 RECEPTOR, COMPOSITIONS AND TREATMENT PROCEDURES
EP1806147A4 (en) USE OF IMMUNOSUPPRESSIVE RECEPTOR
ZA200903574B (en) 2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists
IL196536A0 (en) Selective antagonists of a2a adenosine receptors
EP1750722A4 (en) NEW LYSOPHOSPHIC ACID RECEPTORSELECTIVE ANTAGONISTS
GB0411123D0 (en) High-affinity NY-ESO T cell receptors
EP1773367A4 (en) RECEPTOR ANTAGONISTS FOR EPIDERMAL GROWTH FACTOR AND USE METHOD
EP1636230A4 (en) ADENOSINE A1 RECEPTOR ANTAGONISTS
GB0622684D0 (en) Feed preparation device and method of use
ZA200707714B (en) Highly potent full and partial agonists and antagonists of the nociceptin/orphanin FQ receptor
ZA200900627B (en) Selective antagonists of A2A adenosine receptors
AU2003250685A8 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists